Specific mutated BRCA regions confer different risks of breast, ovarian cancers
the ONA take:
According to a new study published in JAMA, researchers at the The Basser Center for BRCA, the Perelman School of Medicine at the University of Pennsylvania, and the Abramson Cancer Cancer Center, have found specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
For the study, researchers evaluated cancer diagnoses for 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations. Results showed that women who carry a certain subset of BRCA mutations typically found in the Ashkenazi Jewish population have a 69% risk of breast cancer and a 26% ovarian cancer.
Previous research showed that a woman with a BRCA1 mutations automatically has a 59% risk of breast cancer and a 34% risk of ovarian cancer.
The findings suggest that there are certain regions on the BRCA1 and BRCA2 genes that, when mutated, increase a woman's risk for breast cancer, while other mutated regions increase a woman's risk for ovarian cancer.
Specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|